Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10258689 | 0.89 | ALDH1A1 (0.45) | SMN1; SMN2NPC1RAB9AALDH1A1TDP1 | |
| SCHEMBL297761 | 0.82 | ATM (0.40) | SMN1; SMN2ALDH1A1TDP1GAAKMT2A | |
| SCHEMBL297890 | 0.81 | CTSV (0.47) | SMN1; SMN2ALDH1A1TDP1L3MBTL1KMT2A | |
| SCHEMBL34472127 | 0.81 | ALDH1A1 (0.45) | SMN1; SMN2NPC1RAB9AALDH1A1TDP1 | |
| SCHEMBL3515877 | 0.81 | LMNA (0.41) | ALDH1A1TDP1L3MBTL1KMT2ALMNA | |
| SCHEMBL30365116 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1RAB9AALDH1A1TDP1 | |
| SCHEMBL1226349 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1RAB9AALDH1A1TDP1 | |
| SCHEMBL8575821 | 0.79 | ALDH1A1 (0.56) | SMN1; SMN2NPC1RAB9AALDH1A1TDP1 | |
| SCHEMBL15667984 | 0.79 | PKM (0.40) | SMN1; SMN2NPC1RAB9AALDH1A1TDP1 | |
| SCHEMBL1196958 | 0.77 | ALDH1A1 (0.42) | SMN1; SMN2NPC1RAB9AALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | claimed |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2006-01-05 | — | — | US | claimed |
| CN-109503686-B | Novel nucleoside phosphoramidate compounds and uses thereof | 南京圣和药业股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-108546277-B | Novel nucleoside phosphoramidate compounds and uses thereof | 南京圣和药业股份有限公司 | 2021-05-07 | — | — | CN | disclosed |
| CN-108314697-B | Novel nucleoside phosphoramidate compounds and uses thereof | 南京圣和药业股份有限公司 | 2021-05-07 | — | — | CN | disclosed |
| US-9963480-B2 | Nucleoside phosphoramidate compound and use thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2018-05-08 | — | — | US | disclosed |
| US-20150361123-A1 | NOVEL NUCLEOSIDE PHOSPHORAMIDATE COMPOUND AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD (CN) | 2015-12-17 | — | — | US | disclosed |
| EP-2940031-A1 | NOVEL NUCLEOSIDE PHOSPHORAMIDATE COMPOUND AND USE THEREOF | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2015-11-04 | — | — | EP | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8754240-B2 | Process for the manufacture of 4-fluoro-2-methyl-1H-indol-5-ol | ASTRAZENECA AB (SE) | 2014-06-17 | — | — | US | disclosed |
| US-8754240-B2 | Process for the manufacture of 4-fluoro-2-methyl-1H-indol-5-ol | ASTRAZENECA AB (SE) | 2014-06-17 | — | — | US | disclosed |
| WO-2003064413-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | WO | disclosed |
| EP-1313726-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| EP-1311500-A2 | INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-21 | — | — | EP | disclosed |
| EP-1309587-A1 | CINNOLINE COMPOUNDS | AstraZeneca AB (SE) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002012226-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012227-A2 | INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012228-A1 | CINNOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361123-A1 | NOVEL NUCLEOSIDE PHOSPHORAMIDATE COMPOUND AND USE THEREOF | PNP, NUDT1, SLC28A1 | SMN1; SMN2 2162/4885NPC1 346/4885RAB9A 1559/4885 |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | FLT4, NOS3, FLT1 | SMN1; SMN2 4622/4885NPC1 2394/4885RAB9A 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.